No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy-Reference-Cited by-同舟云学术

No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy

Author:

Singh Siddharth¹²³^ORCID,Kim Jihoon²³,Zhu Wenhong³⁴,Dulai Parambir S.¹^ORCID,Sandborn William J.¹^ORCID,Jairath Vipul⁵⁶⁷^ORCID

Affiliation:

1. Division of Gastroenterology; University of California San Diego; La Jolla CA USA

2. Division of Biomedical Informatics; University of California San Diego; La Jolla CA USA

3. Visting Fellow; OptumLabs; Cambridge MA USA

4. Altman Clinical and Translational Research Institute; University of California San Diego; La Jolla CA USA

5. Robarts Clinical Trials, Inc.; London ON Canada

6. Department of Epidemiology and Biostatistics; Western University; London ON Canada

7. Division of Gastroenterology; Department of Medicine; University Hospital; London ON Canada

Funder

ACG Institute for Clinical Research and Education

National Institute of Diabetes and Digestive and Kidney Diseases

Crohn's and Colitis Foundation of America

National Center for Advancing Translational Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

Reference30 articles.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

3. Stopping rules for 5‐ASA in UC need to be redefined;Journal of Gastroenterology and Hepatology;2022-05-12